Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151540 | 0.83 | ESR1 (0.52) | SLC6A4MAOASLC6A2SLC6A3ESR1 | |
| SCHEMBL19734040 | 0.80 | ESR1 (0.55) | SLC6A4SLC6A2SLC6A3ESR1ESR2 | |
| SCHEMBL4441903 | 0.79 | ESR1 (0.48) | SLC6A4SLC6A2SLC6A3ESR1ESR2 | |
| Bromide SCHEMBL11693475 | 0.77 | SLC6A2 (0.63) | SLC6A4MAOASLC6A2SLC6A3ESR1 | |
| SCHEMBL6888087 | 0.74 | SLC6A4 (0.60) | SLC6A4MAOASLC6A2SLC6A3ESR1 | |
| SCHEMBL8361629 | 0.74 | LOXL2 (0.46) | SLC6A4MAOASLC6A2SLC6A3 | |
| SCHEMBL8119219 | 0.73 | SLC6A4 (0.69) | SLC6A4MAOASLC6A2SLC6A3 | |
| SCHEMBL4437809 | 0.72 | POLB (0.58) | ESR1ESR2 | |
| SCHEMBL4441899 | 0.71 | ESR1 (0.48) | SLC6A4SLC6A2SLC6A3ESR1ESR2 | |
| SCHEMBL14269722 | 0.70 | PABPC1 (0.46) | SLC6A4MAOASLC6A2SLC6A3ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | ATR, CHEK1, CHEK2 | SLC6A4 4734/4885MAOA 3114/4885SLC6A2 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.